Levamisole-induced leukoencephalopathy

A medical case of an acute demyelinating process in cerebrum caused by taking levamisole is presented. The issues of pathogenesis and differential diagnosis of levamisole-induced leukoencephalopathy with acute disseminated encephalomyelitis, multiple sclerosis, progressive multifocal leukoencephalopathy, and cerebral lymphoma are discussed.

1. Lionel N.D., Mirando E.H., Nanayakkara J.C., Soysa P.E. Levamisole in the treatment of ascariasis in children. Br. Med. J. 1969;46340–341. doi: 10.1136/bmj.4.5679.340

2. Katzung B.G. (ed): Basic and Clinical Pharmacology. 6th edition. Prentice Hall International Inc., 1995;550–551.

3. Scheinfeld N., Rosenberg J.D., Weinberg J.M. Levamisole in dermatology: a review. Am. J. Clin. Dermatol. 2004;5:97–104. doi: 10.2165/00128071-200405020-00004

4. Sun A., Chiang C.P., Chiou P.S., Wang J.T., Liu B.Y., Wu Y.C. Immunomodulation by levamisole in patients with recurrent aphthous ulcers or oral lichen planus. J. Oral Pathol. Med. 1994;23 172–177. doi: 10.1111/j.1600-0714.1994.tb01108.x

5. Liu H.M., Hsieh W.J., Yang C.C., Wu V.C., Wu K.D. Leukoencephalopathy induced by levamisole alone for the treatment of recurrent aphthous ulcers. Neurology. 2006;67:1065–67. doi: 10.1212/01.wnl.0000237344.06122.79

6. Hawthorne A.B., Hawkey C.J. Immunosuppressive drugs in inflammatory bowel disease. A review of their mechanisms of efficacy and place in therapy. Drugs. 1989;38:267–288. doi: 10.2165/00003495-198938020-00007

7. Moertel C.G., Fleming T.R., Macdonald J.S., Haller D.G., Laurie J.A., Goodman P.J. et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med. 1990;322:352–358. doi: 10.1056/NEJM199002083220602

8. Savarese D.M., Gordon J., Smith T.W., Litofsky N.S., Licho R., Ragland R. et al. Cerebral demyelination syndrome in a patient treated with 5-fluorouracil and levamisole: The use of thallium SPECT imaging to assist in noninvasive diagnosis. A case report. Cancer. 1996;77(2):387–394. doi: 10.1002/(sici)1097-0142(19960115)77:2<387::aid-cncr23>3.0.co;2-x

9. Cheng Y.C., Po H.L. Leukoencephalopathy after levamisole for the treatment of verrucae. Acta Neurol. Taiwan. 2011;20(4):262–266. ant-tnsjournal.com›Mag_Files/20-4/06.pdfPMID:22315177

10. Wu V.C., Huang J.W., Lien H.C., Hsieh S.T., Liu H.M., Yang C.C. et al. Levamisole-induced multifocal inflammatory leukoencephalopathy: clinical characteristics, outcome, and impact of treatment in 31 patients. Medicine (Baltimore). 2006;85(4):203–213. http://dx.doi.org/10.1097/01.md.0000230250.95281.60

11. Stadnyuk Yu.I., Lezina D.S., Vorob’eva O.V. Demyelinating diseases. Treatment of diseases of the nervous system. 2012;2(10):14–21. (in Russ.)

12. Shmidt T.E. Rasseyannii skleroz: rukovodstvo dlya vrachei / T.E.Shmidt, N.N.Yahno. 6-e izd. M.: MEDpress inform, 2017. 280 s. (in Russ.)

13. Shavlovskaya OA. Levamisol-induced leukoencephalopathy: clinical case. Annals of clinical and experimental neurology. 2018;12(3):75–80. (in Russ.) Доступно по: https://elibrary.ru/item.asp?id=35597886 Ссылка действительна на: 27.05.2020.

14. Gilbert J.W. Comment on Xu N., Zhou W., Shuy L., Zhou G,. Zhang N. Clinical and MRI characteristics of Levamisoleinduced leukoencephalopathy in 16 patients. J. Neuroimaging. 2009;13:326–331. J. Neuroimaging. 2011;21(2):e188. doi: 10.1111/j.1552-6569.2010.00466.x

15. Yan R., Wu Q., Ren J., Cui H., Zhai K., Zhai Z. et al. Clinical features and magnetic resonance image analysis of 15 cases of demyelinating leukoencephalopathy induced by levamisole. Experimental and Therapeutic Medicine. 2013;6(1):71–74. http://dx.doi.org/10.3892/etm.2013.1077

16. Bryukhov V.V.: Standardization of MRI studies in multiple sclerosis. Journal of Neurology and Psychiatry. S.S. Korsakov. Special issues. 2016;116(10):27–34. (in Russ.)

17. Schmidt T.E. Progressive multifocal leukoencephalopathy and other neurological symptoms of JC virus activation. Neurological Journal. 2014;19(4):4–10. (in Russ.)

18. Miskin D.P., Ngo L.H., Koralnik IJ. Diagnostic delay in progressive multifocal leukoencephalopathy. Annals of Clinical and Translational Neurology. 2016;3(5):386–391. http://dx.doi.org/10.1002/acn3.301

19. Lima M., Drislane F., Koralnik I. Seizures and their outcome inprogressive multifocal leucoencephalopathy. Neurology. 2006;66:262–4.

20. Bublievsky D.V., Evzikov G.Yu. Primary lymphoma of the central nervous system: clinical picture, diagnosis, modern approaches to treatment. Neurosurgery. 2012;(1):74–81. (in Russ.)

21. DeAngelis L.M., Seiferheld W., Schold S.C., Fisher B., Schultz C.J. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93–100 . J. Clin. Oncol. 2002;20:4643–4648.

22. Laurence D.R., Barnett P.N., Brown M.J. (eds.). Neoplastic disease an immunosuppression. In: Clinical Pharmacology. 8th edition. Churchill Livingstone, New York, 1997;560.

23. Bondy D.C., Bondy P.K., Feinstein A.R. et al (eds.): Antivirus drug. In: The Merck Manual of Diagnosis and Therapy. 14th edition. Merck & Co., Inc., New Jersey, 1982;23–24.

24. Lucchinetti C.F., Kimmel D.W., Pavelko Kand Rodriguez M.: 5-Fluorouracil and levamisole exacerbate demyelination in susceptible mice infected with Theiler’s virus. ExpNeurol. 1997;147:123–129.

25. Chang H.P., Kuo H.C., Yen T.C., Huang C.C. Multifocal demyelinating leukoencephalopathy induced by Levamisole therapy in addition, early steroid treatment is crucial, and the neurotoxic effect of levamisole is not dose-dependent and may be idiosyncratic or immune-mediated. Chang Gung. Med. J. 2006;29(4):90–96.

26. Averchenkov D.M., Bejsheeva M.T., Ivakina E.D., Fominykh V.V., Grazhdantseva L.Yu., Ivashchenko R.A. et al. Clinical case of levamisole-induced multifocal inflammatory leukoencephalopathy. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2019;119(12):106–114. (in Russ.) doi: 10.17116/jnevro2019119121106

27. Israel Z.H., Lossos A., Barak V., Soff er D., Siegal T. Multifocal demyelinative leukoencephalopathy associated with 5-fluorouracil and levamisole. Acta Oncologica. 2000;39(1):117–120. http://dx.doi.org/10.1080/028418600431085

28. Wang C.H., Jeng J.S., Yip P.K. Multifocal leukoencephalopathy induced by levamisole: a case report. Acta Neurol. Taiwan. 2002;11:205–208.

29. Sariaslani P., Ghanbari A., Ghanbari P. Multifocal inflammatory leukoencephalopathy induced by accidental consumption of levamisole: A case report. Iran J. Neurol. 2012;11(2):65–69. http://bmcneurol.biomedcentral.com/articles/10.1186/s12883-015-0467-1

30. Long L., Song Y., Xu L., Xiao B. Levamisole-induced leukoencephalopathy mimicking Baló disease. Neurology. 2015;84(3):328. doi: 10.1212/WNL.0000000000001150

31. Kimmel D.W., Wijdicks E.F.M., Rodriguez M. Multifocal inflammatory leukoencephalopathy associated with levamisole therapy. Neurology. 1995;45(2):374–376. doi: 10.1212/wnl.45.2.374 https://n.neurology.org/content/45/2/374

32. Xu N., Zhou W., Li S., Zhou G., Zhang N., Liang J. Clinical and MRI characteristics of levamisole-induced leukoencephalopathy in 16 patients. J. Neuroimaging. 2009;19(4):326–31. doi: 10.1111/j.1552-6569.2008.00344.x

33. Pradhan S., Gupta R.P., Shashank S., Pandey N. Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis. J. Neurol. Sci. 1999;165:56–61.

34. Yan R., Wu Q., Ren J., H Cui, Zhai K., Zhai Z. Clinical features and magnetic resonance image analysis of 15 cases of demyelinating leukoencephalopathy induced by levamisole. Experimental and therapeutic medicine. 2013;6(1):71–74.